Capricor Therapeutics (CAPR) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- S&P 500, Nasdaq futures edge up as chip stocks gain; US-Iran tensions in focus
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Oil rises as US-Iran conflict clouds peace prospects
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Palantir partnership fails to save Rackspace stock after brutal guidance slash
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 14, 2023 4:05 PM EST-Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy-
-On Track to Report Interim Futility Analysis in Fourth Quarter of 2023; Successful Outcome Would Trigger Milestone Payment to Capricor Under Commercialization and Distribution Deal with Nippon Shinyaku-
-Positive FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002s Path Towards a Biologics License Application Submission-
-Conference Call and Webcast Today at 4:30 p.m. ET-
SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) --... More
